Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062594 | 0.84 | CYP2A6 (0.50) | CYP2A6ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL12013593 | 0.81 | CYP2A6 (0.56) | CYP2A6ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL4453260 | 0.81 | CYP2A6 (0.56) | CYP2A6ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL8895165 | 0.79 | CYP2A6 (0.54) | CYP2A6ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL6910872 | 0.79 | CYP2A6 (0.54) | CYP2A6ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL6404480 | 0.79 | CYP2A6 (0.54) | CYP2A6ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL8578429 | 0.79 | CYP2A6 (0.54) | CYP2A6ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL5691676 | 0.78 | ALDH1A1 (0.48) | CYP2A6ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL30066580 | 0.78 | ALDH1A1 (0.48) | CYP2A6ALDH1A1HSD17B10TSHRTDP1 | |
| SCHEMBL10917220 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1830841-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1830841-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068992-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
| US-5919797-A | DIAGNOSIS, THERAPY PSYCHOLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1997040010-A1 | HALOGENATED NAPHTHYL METHOXY PIPERIDINES FOR MAPPING SEROTONIN TRANSPORTER SITES | EMORY UNIVERSITY (US) | 1997-10-30 | — | — | WO | disclosed |
| EP-0043936-A1 | Method for the preparation of benzo-1,2-dithiol-3-thiones | BASF Aktiengesellschaft (DE) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD3B1 | CYP2A6 582/4885ALDH1A1 119/4885HSD17B10 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.